As of Feb 11
| +0.11 / +0.38%|
The 32 analysts offering 12-month price forecasts for AstraZeneca have a median target of 35.64, with a high estimate of 50.30 and a low estimate of 26.97. The median estimate represents a +22.26% increase from the last price of 29.15.
The current consensus among 33 polled investment analysts is to Buy stock in AstraZeneca. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.